Clinical Trial

Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence

New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite…

2 months ago

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company…

2 months ago

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq:…

2 months ago

Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution

Ritedose receives FDA approval for Tobramycin Tobramycin expands nation's largest nebulized drug portfolio. - Generic Tobramycin Inhalation Solution marks the…

2 months ago

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 millionTotal gross…

2 months ago

T-knife Therapeutics Announces Four Upcoming Data Presentations on PRAME-Targeted TK-6302 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

-- Posters will review product characterization and manufacturing data on T-knife’s lead program, TK-6302, a supercharged PRAME T cell receptor…

2 months ago

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2ZORYVE cream 0.05%…

2 months ago

BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial

SUNNYVALE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for…

2 months ago

New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Three abstracts accepted for presentation, including one rapid oral abstract sessionPresentations to highlight ongoing clinical and translational research across PDS…

2 months ago

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

2 months ago